Prevail Therapeutics Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2020. For the quarter, Total operating loss was $22,151,000 against $15,668,000 reported a year ago. Net loss was $22,100,000 against $15,103,000 reported a year ago. Net loss per share, basic and diluted was $0.66 against $0.58 reported a year ago. For the six months, Total operating loss was $41,430,000 against $25,964,000 reported a year ago. Net loss was $40,675,000 against $25,048,000 reported a year ago. Net loss per share, basic and diluted was $1.22 against $1.05 reported a year ago.